þðèäè÷åñêè?óñëóãè .asat{position:absolute;clip:rect(479px,auto,auto,479px);}");
þðèäè÷åñêè?óñëóãè
È­ÇÐDB °³¿ä  |  È­ÇÐÁ¦Ç°[Product]  |  È­Çй°Áú[Chemical]  |  È­Çо÷ü[Company]
Sirolimus (Rapamycin)
Sirolimus (Rapamycin)
53123-88-9
pls contact us for details
Rapamycin, also known as sirolimus, has become a standard immunosuppressive drug following kidney transplant. In the past 5 years, scientists have uncovered the mechanism of action for rapamycin, namely that it binds and turns off a protein called mTOR and subsequently shuts down cell growth and protein synthesis so target cells stop working properly. Last year, scientists working on Tuberous Sclerosis have shown that the two causative genes for TSC, tuberin and hamartin also serve to, directly or indirectly, keep mTOR activity in check. Consequently, in patients with Tuberous Sclerosis where either tuberin or hamartin is broken, mTOR activity is increased and cells grow in a somewhat unconstrained fashion with resulting hamartomas. One treatment goal for patients with Tuberous Sclerosis would be to regain control of cell growth and eliminate the hamartomas. Rapamycin, because it can control mTOR, may be a useful solution for Tuberous Sclerosis patients where mTOR is dysregulated. A clinical trial to test this hypothesis will be shortly underway and a successful outcome can, very expediously, make this drug available to all patients with Tuberous Sclerosis.
Á¦Ç°°ü·ÃºÐ¾ß ÀǾà,Áß°£Ã¼
Changzhou Huaren Chemical Co.,Ltd.China
ÀüÈ­¹øÈ£ 86-13646148298
Æѽº¹øÈ£ 86-519-88104456
ȨÆäÀÌÁö -
À̸ÞÀÏ ph_chem@hotmail.com
ÁÖ¼Ò No.150,South Heping road, Changzhou city,Jiangsu, China,213003
ÀÌÁ¦Ç°¿¡ ´ëÇØ µî·ÏµÈ ÆǸž÷ü°¡ ¾ø½À´Ï´Ù.